Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating

Celcuity (CELC) is back in focus after publishing Phase 3 VIKTORIA-1 data on its breast cancer drug candidate in the Journal of Clinical Oncology, alongside fresh analyst coverage that has drawn renewed attention from investors.

See our latest analysis for Celcuity.

The VIKTORIA-1 publication and recent analyst attention come after a sharp rerating, with Celcuity’s 1 year total shareholder return above 10x. Its 30 day and 90 day share price returns of 9.19% and 15.20% suggest momentum has recently been building despite some short term pullbacks.

If this kind of oncology data has you rethinking the sector, it could be a good moment to see what other specialised healthcare names are doing through our curated set of 36 healthcare AI stocks

After a very large 1 year total shareholder return and a recent price near US$114, Celcuity still trades at a discount to one analyst’s US$190 target. This raises the question of whether there is more potential upside or if future growth is already fully reflected in the current price.

Most Popular Narrative: 2.2% Undervalued

Celcuity’s most followed narrative pegs fair value at $116.70, just above the last close of $114.11, which helps explain why sentiment looks finely balanced here.

Celcuity currently has no revenue. Analysts are forecasting revenue to reach $607.1 million by March 2029. As a pre-revenue company, Analysts expect Celcuity to achieve a profit margin of 25.1% in 3 years time.

Read the complete narrative.

Curious what kind of revenue ramp and margins are baked into that fair value, and how much earnings power the narrative assumes for gedatolisib by the late 2020s? The underlying story leans on high growth forecasts, a sizeable profit swing and a premium earnings multiple usually reserved for mature leaders in other sectors, all working together to support that $116.70 figure.

Result: Fair Value of $116.70 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on smooth clinical and regulatory progress, and any delay in approvals or weaker than expected trial data could quickly challenge today’s fair value story.

Find out about the key risks to this Celcuity narrative.

Another View: Rich Multiples Against Peers

The narrative labels Celcuity about 2.2% undervalued, yet its P/B of 45.1x is far higher than the US Biotechs industry at 2.6x and the peer average of 6.8x. This points to a lot of optimism already in the price, which raises the question: where does that leave the risk-reward for you?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment finely balanced between optimism and caution, this is a good moment to review the full picture yourself and act while the story is still taking shape. You can start with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock story. Widen your search with focused idea lists built from clear fundamentals.

• Target potential mispricings by scanning for quality names trading below what their numbers suggest through 49 high quality undervalued stocks.
• Strengthen your income stream by hunting for companies with generous payouts and resilience using 15 dividend fortresses.
• Give yourself a head start on underfollowed opportunities by filtering for quietly robust businesses via the screener containing 27 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com